You might also like
United-Guardian, Inc. (UG) is a Delaware-based company specializing in the manufacturing, marketing, research, and development of innovative products across various industries. The company operates through its Guardian Laboratories division and focuses on creating high-quality formulations for personal care, pharmaceuticals, medical applications, and sexual wellness. UG's products are marketed globally, leveraging a strong distribution network and a commitment to natural and sustainable solutions.
-
Cosmetic Ingredients - Develops multifunctional hydrogel formulations under the Lubrajel® brand, offering sensory enhancement, hydration, and texture for personal care products. Focuses on natural and environmentally friendly solutions, with some products certified by the COSMOS standard.
-
Pharmaceuticals - Produces FDA-approved prescription drugs, including Renacidin® for preventing and dissolving calcifications in catheters and Clorpactin® WCS-90, a chlorine-based topical antimicrobial. Distributed through full-line drug wholesalers to pharmacies, hospitals, and government agencies.
-
Medical Lubricants - Manufactures water-based gel formulations designed for lubrication and sensory enhancement in medical device applications, sold directly to medical device manufacturers.
-
Sexual Wellness Ingredients - Markets the Natrajel™ line of sexual wellness ingredients, introduced in 2024, through a distribution agreement with Brenntag Specialties, targeting the Americas.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Andrea Young Executive | Principal Financial Officer | Andrea Young has served as the Principal Financial Officer at UG since May 2018, and concurrently holds roles as Controller, Treasurer, Secretary, and Human Resources Manager, playing a key part in financial operations and corporate governance. | ||
Donna Vigilante Executive | President and Principal Executive Officer | Donna Vigilante has been a key figure at UG, serving as President and Principal Executive Officer since June 9, 2023, and previously held roles such as Vice President – Research and Development from May 2020 to June 2023 as well as R&D Manager and Chemist prior to that. Her leadership has been instrumental in driving product development and sustainability initiatives at the company. | View Report → | |
Peter A. Hiltunen Executive | Senior Vice President - Production & Procurement | Peter A. Hiltunen has been serving as Senior Vice President - Production & Procurement at UG since April 2020. He began his career with UG as Production Manager in 1982 and served as Vice President from July 2002 to April 2020, contributing significantly to the company’s operational success. | ||
Arthur M. Dresner Board | Director | Counsel at Duane Morris LLP | Arthur M. Dresner has been a Director at United-Guardian, Inc. since 1997. In addition, he serves as the Chairman of the Audit Committee and a member of the Compensation Committee , and he is active as Counsel at Duane Morris LLP since August 2007. | |
Catherine Kolinski Board | Director | Catherine Kolinski is the Director at United-Guardian, Inc. since January 2, 2024. She brings over 30 years of experience from previous executive roles at Ashland Inc. as Vice President of North America Consumer Specialties and at Geltor Inc. as a Consultant. | ||
Ken Globus Board | Chairman of the Board | Ken Globus has had a longstanding career at UG, having held roles including General Counsel, President and Principal Executive Officer, and CFO before becoming Chairman of the Board in September 2009. He led the company as President from July 1988 until October 2022, demonstrating extensive leadership, legal, and financial expertise. | ||
Lawrence F. Maietta Board | Director | Partner at PKF O’Connor Davies, LLP | Lawrence F. Maietta has served as a Director at United-Guardian, Inc. since 1994 and has also contributed as an advisor to the Audit Committee and a member of the Compensation Committee. With a background that includes serving as Controller from October 1991 to November 1997 and over 35 years of CPA experience, he has played a key role in the company’s financial oversight. | |
S. Ari Papoulias Board | Director | Principal of ChemRise LLC | S. Ari Papoulias has served as a Director at UG since 2016 and brings extensive industry expertise from his ongoing role as Principal of ChemRise LLC since 2016. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Customer A | Largest distributor for cosmetic ingredients | Cosmetic Ingredients | Revenue in 2024: $5.39 million (approx. 44.3% of total $12.18 million ) |
Customer B | Key distributor | All | Revenue in 2024: $2.24 million (approx. 18.4% of total $12.18 million ) |
Customer C | Key distributor | All | Revenue in 2024: $1.83 million (approx. 15.0% of total $12.18 million ) |
Customer D | Key distributor | All | Revenue in 2024: $1.33 million (approx. 10.9% of total $12.18 million ) |
Recent press releases and 8-K filings for UG.
- Governance & Proxy Vote Results: United Guardian Inc held its 2025 Annual Meeting on May 15, 2025, where stockholders voted on board elections (e.g., Ken Globus, Lawrence F. Maietta) and inspectors confirmed proxies represented 83% of outstanding shares .
- Meeting Outcomes: The meeting approved executive compensation proposals and ratified Grassi & Co., CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 .
- Financial Performance: FY 2024 saw a 12% sales increase with improved retained earnings and stockholders’ equity, while Q1 2025 experienced mixed performance, including a decline in cosmetic ingredient sales .
- Tariff & Supply Chain Impact: Global tariff uncertainties, particularly extreme China tariffs, are driving up raw material costs even though major supply chain disruptions have not been reported .
- Forward Strategy & Product Pipeline: The company is focusing on expanding its pharmaceutical presence with initiatives for Renacidin, launching new products in sexual wellness and cosmetic ingredients, and reviewing key distributor contracts with Ashland while dismissing stock buybacks due to a small public float .
- Net sales declined to $2.48M in Q1 2025 from $3.25M in Q1 2024, with net income dropping to $560.9K compared to $925.4K last year.
- Medical lubricant and pharmaceutical sales increased by 43% and 23% respectively, while cosmetic ingredient sales fell by 63%, primarily due to reduced orders from ASI.
- Management highlighted concerns over lingering tariff impacts and a slow start to 2025, emphasizing that the decrease in cosmetic ingredients was driven by excess inventory issues in China.
- Net sales increased by 12% from $10.89M in FY 2023 to $12.18M in FY 2024, with net income rising from $2.58M to $3.25M and EPS improving from $0.56 to $0.71, indicating strong financial growth.
- Sales in key segments drove performance: cosmetic ingredients surged by 32% and medical lubricants by 16%, while pharmaceutical sales dipped by 5% due to supply issues with Renacidin impacting early 2024.